[{"address1": "828 Winter Street", "address2": "Suite 300", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "857 524 2466", "website": "https://xiliotx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 73, "companyOfficers": [{"maxAge": 1, "name": "Dr. Rene  Russo BCPS, Pharm.D.", "age": 48, "title": "President, CEO & Director", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 875130, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Frankenfield", "age": 41, "title": "Chief Operating Officer", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 704848, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Katarina  Luptakova M.D.", "age": 47, "title": "Chief Medical Officer", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 591917, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kevin M. Brennan", "age": 53, "title": "Senior VP of Finance & Accounting", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Uli  Bialucha Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.975, "open": 1.0, "dayLow": 0.965, "dayHigh": 1.05, "regularMarketPreviousClose": 0.975, "regularMarketOpen": 1.0, "regularMarketDayLow": 0.965, "regularMarketDayHigh": 1.05, "beta": -0.199, "forwardPE": -1.4510447, "volume": 728400, "regularMarketVolume": 728400, "averageVolume": 459359, "averageVolume10days": 1556880, "averageDailyVolume10Day": 1556880, "bid": 0.714, "ask": 1.25, "bidSize": 200, "askSize": 200, "marketCap": 44447136, "fiftyTwoWeekLow": 0.5, "fiftyTwoWeekHigh": 1.93, "priceToSalesTrailing12Months": 9.620592, "fiftyDayAverage": 1.02896, "twoHundredDayAverage": 0.9756, "currency": "USD", "enterpriseValue": 3422334, "floatShares": 22620385, "sharesOutstanding": 45718100, "sharesShort": 175269, "sharesShortPriorMonth": 396085, "sharesShortPreviousMonthDate": 1730332800, "dateShortInterest": 1732838400, "sharesPercentSharesOut": 0.004, "heldPercentInsiders": 0.43825, "heldPercentInstitutions": 0.29497, "shortRatio": 0.42, "shortPercentOfFloat": 0.0047999998, "impliedSharesOutstanding": 45718100, "bookValue": 0.477, "priceToBook": 2.038155, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -62803000, "trailingEps": -1.55, "forwardEps": -0.58, "enterpriseToRevenue": 0.741, "enterpriseToEbitda": -0.055, "52WeekChange": 0.6956521, "SandP52WeekChange": 0.2729931, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "XLO", "underlyingSymbol": "XLO", "shortName": "Xilio Therapeutics, Inc.", "longName": "Xilio Therapeutics, Inc.", "firstTradeDateEpochUtc": 1634909400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "a29df73e-2ef5-3eed-8f1d-9d3cdeb4d4fb", "messageBoardId": "finmb_365333564", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.9722, "targetHighPrice": 5.0, "targetLowPrice": 4.0, "targetMeanPrice": 4.5, "targetMedianPrice": 4.5, "recommendationMean": 1.66667, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 61259000, "totalCashPerShare": 1.394, "ebitda": -62428000, "totalDebt": 8415000, "quickRatio": 1.611, "currentRatio": 1.665, "totalRevenue": 4620000, "debtToEquity": 40.121, "revenuePerShare": 0.105, "returnOnAssets": -0.52579, "returnOnEquity": -1.70958, "freeCashflow": -3042250, "operatingCashflow": -17648000, "grossMargins": 1.0, "operatingMargins": -6.5413203, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-28"}]